Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
The purpose of the study is to demonstrate clinical efficacy of the investigational
 trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or
 2+ (FISH-) expressing advanced or metastatic breast cancer (stage III b/IV) which has
 progressed after endocrine therapy.

 Ertumaxomab is a trifunctional bispecific antibody targeting Her-2/neu and CD3 on T cells.
 Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new
 antibody class has the capability to redirect T cells and accessory cells (e.g. macrophages,
 dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to
 preclinical data, trifunctional antibodies activate these immune cells, which can trigger a
 complex anti-tumor immune response.
An open-label, non-randomized, uncontrolled, one-stage, phase II study evaluating the
 efficacy and safety of the investigational trifunctional bispecific antibody ertumaxomab
 (anti-Her-2/neu x anti-CD3) for the treatment of hormone therapy refractory advanced or
 metastatic breast cancer tumours (stage IIIb or IV) which are known to express HER-2/neu (1+
 or 2+/FISH negative).Ertumaxomab will be administered at 7 day intervals by constant rate 3
 hour intravenous (i.v.) infusions according to the following sequential dose schedule: 10 µg
 (day 0) and thereafter 100 µg flat doses once every 7 days (± 1 day) for a maximum of up to
 12 weeks or until disease progression or any other unacceptable toxicity.
Inclusion Criteria:

 -  Signed and dated informed consent form

 -  Women ≥ 18 years, negative pregnancy test at screening life expectancy of at least 6
 months

 -  Locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma
 of the breast

 -  Measurable disease, defined as at least one lesion that is measurable in one dimension
 (RECIST)

 -  HER-2/neu expression 1+ or 2+ / FISH negative

 -  Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive

 -  Prior adequate endocrine therapy for advanced or metastatic disease

 -  Disease progression during or after endocrine therapy

 -  No prior treatment with mouse or rat antibodies

 -  ECOG performance score of ≤ 1

 -  Adequate hematological, liver and kidney function

 Exclusion Criteria:

 -  Women who are pregnant or breast-feeding

 -  Known HIV infection or Presence of autoimmune disease or other Concurrent
 non-malignant co-morbidities that are uncontrolled

 -  History or symptoms indicative of brain or CNS metastases

 -  Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before
 study entry (except in situ carcinoma of the cervix or adequately treated basal cell
 carcinoma of the skin)

 -  Documented acute or chronic infection requiring antibiotic treatment

 -  Any concurrent chemo-, hormonal, immuno- or corticoid therapy

 -  Any prior chemotherapy for advanced or metastatic disease

 -  Any concurrent investigational treatment for advanced or metastatic disease

 -  History of relevant cardiovascular disease as follows:

 -  Left ventricular ejection fraction (LVEF) below the institution's lower limit of
 normal, based on echocardiography (ECG) at rest

 -  Uncontrolled or symptomatic congestive heart failure (New York Heart Association
 (NYHA) > 2

 -  Uncontrolled or symptomatic arrhythmia and/or angina pectoris

 -  Myocardial infarction during the last 2 years